THE EFFECT OF GLUCAGON ON HEPATIC CELLULAR ENERGETICS DURING A --ETC(U)
1979 J J PROCTOR, J J WOOD, W G PALLADIO N00014-76-C-0595

UNCLASSIFIED
The Effect of Glucagon on Hepatic Cellular Energetics
During a Low Flow State

H. J. Proctor, M.D., F.A.C.S.
James J. Wood, Ph.D.
William G. Palladino, M.S.

Presented at the 4th Tripartite Meeting, Oxford, England,

Trauma Section and the Laboratory of Cellular Bioenergetics
Department of Surgery, University of North Carolina,
Chapel Hill, N. C., 27514

This work supported in part by ONR Contract #N00014-76-

This document has been approved for public release and sale; its distribution is unlimited.
ABSTRACT

An investigation of the effect of glucagon on liver high energy phosphate concentration during a low flow state is presented. Two groups of dogs were subjected to a 120 minute period of hemorrhagic hypotension followed by re-infusion of shed blood plus additional normal saline to restore the central venous pressure to 10 cm H₂O. One group received in addition, intravenous glucagon. Despite a significant increase in portal flow and oxygen delivery, and a significant increase in liver glucose associated with glucagon administration, there was significant impairment in the ability of the liver to regenerate ATP. Evidence is presented to show the decreased ATP concentration was not hepatic blood flow related but was presumably due to increased catabolism.
INTRODUCTION

An increase in portal vein blood flow and pressure after glucagon infusion is now firmly documented\(^{(12)}\). This increase in flow and pressure has been attributed to arterio-venous shunting as well as a decrease in vascular resistance in the mesenteric bed\(^{(15,5,9)}\). As a logical consequence of this response, many authors have advocated glucagon administration to augment portal vein flow after hepatic artery ligation or major hepatic resection associated with trauma\(^{(2,10,11,6)}\). In addition, glucagon in large intravenous boluses has been recommended to maximize hepatic oxygenation secondary to blood loss associated with liver trauma or generalized hemorrhagic hypotension\(^{(16)}\). However, the influence of glucagon on portal vein blood flow during a period of sustained hypotension is less well understood.

Glucagon also has a metabolic effect on the liver by activating cyclic AMP, leading to increased gluconeogenesis and glycogenolysis\(^{(13)}\) with a concomitant increase in the need for oxygen. Mays\(^{(11)}\) pointed out that a superimposed need for additional oxygen by glucagon administration in the presence of an already compromised hepatic circulation may severely restrict hepatocyte respiration. Fredlund, et. al.\(^{(3)}\) have in fact demonstrated a severe curtailment of hepatocyte respiration by glucagon administration. The net beneficial effect of the clinical use of this drug is therefore still open to question.

In view of the apparent complex hemodynamic and metabolic effects of glucagon on hepatic function, this investigation was undertaken to determine the effect of this hormone in dogs on: (a) hepatic energy metabolism and (b) portal vein blood flow, following a sustained episode
METHODS

Non-fasted, non-splenectomized mongrel dogs were used and handled in accordance with NIH standards for humane treatment of animals. All dogs were maintained in an anesthetized state throughout the experimental procedure with pentobarbital sodium (35 mg/kg) administered intravenously. At the start of the experiment, the dogs were intubated, connected to a Harvard ventilator, and the FIO$_2$ adjusted to achieve an arterial pO$_2$ of 80-100 mm Hg. Both femoral arteries and veins were then cannulated to allow the monitoring of arterial and central venous pressure, arterial blood sampling, and the infusion of blood and normal saline intravenously. A celiotomy was performed and a P.E. 50 catheter inserted into a branch of the superior mesenteric vein and the tip advanced into the portal vein to obtain portal venous blood samples. Non-cannulating electromagnetic flow probes* were then placed around the portal vein and hepatic artery.

Measurement of arterial and portal vein pO$_2$** allowed the calculation of percent O$_2$ saturation from the dog oxy-hemoglobin dissociation curve. Arterial and portal venous oxygen content were calculated according to the formula: [Hemoglobin*** x 1.34 x percent O$_2$ saturation]. Oxygen delivery to the liver was calculated as the product of oxygen content and flow, adding together the contribution of the hepatic artery and portal vein.

A liver biopsy was obtained after in situ freezing and quickly placed

*Carolina Medical Electronics, King, N. C.
in liquid nitrogen using a technique developed in this laboratory(14).
Samples thus obtained were assayed for liver ATP, ADP, inorganic phosphate
(Pi), glucose, glucose-6-phosphate (G-6-P) and lactate concentrations
using enzymatic, fluorometric methods according to Lowry and Passoneau(8).
Concentrations of inorganic phosphate and the ATP/ADP ratio were used to
compute the free energy change of ATP hydrolysis ($\Delta G$) as described by
Hassinen(4).

After baseline sampling, the mean arterial pressure was reduced to
50 mm Hg over a 15 minute period by arterial bleeding into a reservoir.
This pressure was maintained for 90 minutes by intermittent withdrawal
and re-infusion of blood, at which time the mean arterial pressure was
reduced by further arterial bleeding to 35 mm Hg. This pressure was
maintained for 30 minutes following which the measurements described above
were repeated, and the dogs were alternately assigned to one of two
treatment groups.

Group I dogs were resuscitated by re-infusing all shed blood plus
additional normal saline to either restore the mean arterial pressure
to baseline values or to elevate the central venous pressure to 10 cm
H$_2$O, whichever occurred first. These conditions were maintained throughout
the remainder of the study. Group II dogs were treated in an identical
manner except they received in addition a 6 ug/Kg bolus of glucagon* along
with the re-infusion of their shed blood, and thereafter received a
continuous infusion of glucagon at a rate of 3 ug/Kg/min.

The measurements described above were repeated in both groups, 30
minutes ($S + 30'$) and 240 minutes ($S + 240'$) after the start of resuscitation.

*Glucagon kindly provided by Eli Lilly & Co., 307 E. McCarty St.,
Indianapolis, Ind., 46206
Data were averaged for each sample time and Group I contrasted with Group II using the Student t-test.

It was the authors' desire to create a workable experimental model in which adequate intravascular volume was available for any potential redistribution by glucagon, at the same time creating a state in which the animal's systemic arterial pressure was not necessarily returned to baseline values. The 120 minute period of hypotension was arrived at by trial and error, and was selected to compliment the combined surgical trauma of celiotomy and multiple liver biopsy. Although the criteria for the completion of intravascular volume replacement were as described above, the mean arterial pressure was not restored to baseline in any dog. Intravascular volume replacement was, as a result, governed solely by the central venous pressure. The failure of arterial pressure to return to the baseline value is thus not an experimental variable but results from experimental design. (Fig. 1)

RESULTS

Due to the severity of the experimental procedure, four animals expired without completing the entire six hour protocol leaving 21 animals (10 control, 11 glucagon treated) from whom data were collected at all sample times. Data from non-survivors are not included in the subsequent analysis.

(a) Effect of glucagon on portal flow

As part of the normal response to resuscitation, four of ten dogs in Group I increased their portal vein flows above their respective baseline value at (S + 30'). Glucagon administration in Group II animals was associated with a variable incidence of increased
portal-vein flow. (Seven of eleven dogs had increased portal vein flow at S + 30'.) When Groups I and II are contrasted, with four of ten and seven of eleven manifesting an increased portal vein flow at S + 30' respectively, it is apparent that glucagon did not significantly affect the number of times increased portal blood flow was observed (p>.1). However, when blood flow did increase following glucagon administration, the magnitude of the increase was significantly greater (p<.05) than the magnitude of increase in the non-treated animals. (Fig. 2) This increase was manifested only at the S + 30' sample time, presumably in response to the 6 ug/Kg bolus. The increase in portal vein flow was no longer manifested four hours after resuscitation (S + 240') during which time the Group II dogs were receiving 3 ug/Kg/min. of glucagon. There was no observable effect of glucagon on hepatic artery flow at any time following administration.

(b) Effect of glucagon on liver energy metabolism

To determine if liver concentrations of adenine nucleotides and glycolytic intermediates were affected by the increased portal vein flow following glucagon administration, the data were analyzed first by excluding the four Group II animals which did not manifest an increase in portal vein flow after glucagon administration. To determine any direct, non-flow related effect of glucagon, the data from all Group I animals were utilized for comparison. The results were not significantly different (p>.1) whether the four animals without an increased portal vein flow were included or excluded. Accordingly, the data is presented in the form of a comparison between all Group I versus all Group II animals.
As evident in Table I, liver ATP concentrations decreased (p<.01) by the end of shock in both groups. Following resuscitation, the ATP concentrations improved but remained lower than control values in both groups. The ATP concentrations in Group I, however, were significantly (p<.05) lower than Group I at both sample times following resuscitation (S + 30', S + 240').

ADP and Pi concentrations remained within the normal range following resuscitation in both groups, with no significant differences between groups. The relationships between ATP and lower energy intermediates are also presented in Table I as are the ATP/ADP ratios and the ΔG values. There were no significant differences between groups for liver G-6-P, or lactate (Table II). Liver glucose was significantly (p<.05) increased in the glucagon treated animals at S + 30'.

Oxygen delivery to the liver, expressed as the combined contribution of the hepatic artery and portal vein flows, was significantly (p<.01) increased by glucagon administration (Table III). As already noted, hepatic arterial flow was not affected by glucagon. Oxygen content was significantly (p<.05) increased in portal blood at S + 30', thus, the increased oxygen delivery resulted from both an increased portal vein flow and an increased oxygen content.

DISCUSSION

The major observation in this study is the significantly lower ATP values in the glucagon treated animals following resuscitation from shock. While ATP values never reached control levels during resuscitation in either group, ATP was 45% lower at (S + 30') in those animals treated with glucagon as compared to the non-treated group. This difference increased
at (S + 240') to 55%. Clearly, glucagon created an adverse effect on regeneration of this high energy compound to control levels. ADP and inorganic phosphate were also lower at (S + 240') in the glucagon group but these differences were not statistically significant. No difference between the two treatment groups was found in the values of G-6-P or lactate following resuscitation.

It could be argued that the effect of glucagon was to cause arterio-venous shunting with the liver, thus excluding hepatic tissue from adequate perfusion. Despite the augmented portal vein flow, intra-hepatic re-distribution of blood might also have resulted from the slightly lower arterial pressures and flows noted in Group II after re-infusion. This effect was most pronounced at (S + 240'). However, neither of these explanations are supported by the data, as the liver lactate concentrations returned toward baseline equally in both groups. The implication is that perfusion was adequate for lactate washout, and oxygen delivery was sufficient for aerobic respiration.

Grossly, the livers became dark and cyanotic during the shock period, but promptly returned to the normal red color with re-infusion of shed blood and saline, with only occasional small patches of persistent dark mottling. Care was always taken to obtain the biopsies from a normal appearing portion of the liver. The obvious gross reperfusion of the tissue further argues against intra-hepatic redistribution of blood or A-V shunting in the glucagon treated animals. These observations suggest that the mechanism by which glucagon causes a decreased hepatic ATP concentration does not appear to be flow related in view of the lack of difference noted when the data from Group II animals was analyzed with and without the four animals not experiencing
an increased portal flow after glucagon. This variable response of
portal vein flow after glucagon has not been previously commented on and
probably results from differences in our experimental model as compared to
others(15,5,9,18).

The rise in liver glucose noted in the study after glucagon adminis-
tration is consistent with the observation that glucagon depletes liver
glycogen. Inability to phosphorylate glucose does not appear to be
a factor in the decreased ATP concentration in view of the normal
concentrations of G-6-P present in the post-shock biopsies. The return
of lactate toward normal values associated with normal and occasionally
greater than normal availability of oxygen, along with the absence of
significant changes in the free energy of hydrolysis, indicate that the
cytochrome chain was probably not compromised in its ability to transfer
electrons, and that oxygen was available in sufficient quantities as the
final electron acceptor. ATP:ADP ratios were normal in both groups after
resuscitation. This fact, along with the return of inorganic phosphate
to control levels indicates the absence of non-specific hydrolysis of
nucleotides as noted by Chaudry(1).

It would appear that the failure of ATP to return to baseline in Group I
indicates either decreased biosynthesis or increased utilization of this
metabolite, or possibly both.

Yamazaki, et. al.(20) reported a stimulation of ATP-ase activity
and ATP-dependent K+ accumulation in rat livers treated with glucagon. These
studies showed a difference in the sensitivity of control and glucagon mito-
chondria to inhibition by antimycin, suggesting a possible hormonal effect
in the Complex III region of the respiratory chain. Since the chain appears
to be adequately transferring electrons, the effect might be assumed to be
in the coupling mechanism itself. Titheradge and Coore\textsuperscript{(17)} recently demonstrated that the pH - gradient across the mitochondrial membrane is increased by acute glucagon treatment. They also confirm that glucagon treatment causes a stimulation of state 3 respiration with the pyruvate-maleate couple indicating a tighter coupling between oxidation and phosphorylation. Other studies on the effect of glucagon treatment by Yamazaki\textsuperscript{(19)} on oxidative phosphorylation have shown that the hormone stimulates the rate of phosphorylation of ADP in isolated mitochondria which could also be interpreted as an increase in coupling ability.

A study by Lindberg et. al.\textsuperscript{(7)} on rats subjected to hemorrhagic shock demonstrated that ATP levels were not restored to normal 30 minutes after resuscitation; a finding similar to the data presented in this study. Witte et. al.\textsuperscript{(18)} found that administration of glucagon to dogs sharply increased portal oxygen delivery, as also shown in our experiments, but no improvement in hepatic tissue oxygenation was observed at high FIO\textsubscript{2}. The hepatic artery was previously ligated in these animals. These data suggested a rise in hepatic oxygen utilization as an explanation. This would be consistent with an increase in ATP production as reported by Yamazaki\textsuperscript{(19)}. In the studies by Fredlund et. al.\textsuperscript{(3)} an elevation of intracellular hepatic enzymes after hepatic artery ligation and glucagon treatment support the concept that the hypercatabolic effect of this hormone far outstrips augmented oxygen delivery and possibly enhanced ATP production. It would thus appear that the depleted pool of ATP observed in our study, following resuscitation from severe hemorrhage, is a reflection of both an augmented production and an increased utilization of the ATP, with utilization greatly in excess of any increase in production. The results further indicate that the depleted concentration of ATP in liver
after glucagon administration was due primarily to a metabolic effect and not circulatory changes.

In light of increasing adverse experimental evidence of the effect of glucagon on hepatic energy metabolism it would seem that even in the face of an augmented portal vein blood flow and increased oxygen delivery, hepatic function is not improved by intravenous infusion of glucagon, and in fact may be adversely affected. It is felt that the routine use of this hormone in hemorrhagic shock should be discontinued and that specific criteria for its use in this context needs to be established.
REFERENCES.

References cont'd:


LEGEND - TABLE I

Concentrations of ATP, ADP and inorganic phosphate (Pi) as well as calculated ATP:ADP ratios and free energy of hydrolysis (ΔG). Means ± SEM. Significant differences compared with corresponding control group. C = controls (n=10); G = glucagon treated (n=11) (S + 30' = 30 minutes post-resuscitation; S + 240' = 240 minutes post-resuscitation). *p<.05
<table>
<thead>
<tr>
<th>GROUP</th>
<th>ADP (umol/g)</th>
<th>ATP (umol/g)</th>
<th>Pi (umol/g)</th>
<th>ATP/ADP</th>
<th>ΔG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>0.72±.09</td>
<td>2.42±.13</td>
<td>1.78±.40</td>
<td>0.64±.06</td>
<td>-8.27±.23</td>
</tr>
<tr>
<td></td>
<td>0.52±.05</td>
<td>0.62±.08</td>
<td>0.90±.95</td>
<td>0.52±.05</td>
<td>-7.92±.09</td>
</tr>
<tr>
<td></td>
<td>1.68±.27</td>
<td>2.66±.31</td>
<td>4.90±.95</td>
<td>0.52±.05</td>
<td>-6.68±.18</td>
</tr>
<tr>
<td></td>
<td>1.00±.20</td>
<td>2.64±.32</td>
<td>3.80±.90</td>
<td>0.52±.05</td>
<td>-6.50±.14</td>
</tr>
<tr>
<td></td>
<td>2.40±.43</td>
<td>2.64±.43</td>
<td>2.38±.64</td>
<td>0.52±.05</td>
<td>-7.60±.25</td>
</tr>
<tr>
<td></td>
<td>2.40±.43</td>
<td>3.55±.40</td>
<td>2.46±.75</td>
<td>0.52±.05</td>
<td>-7.95±.19</td>
</tr>
<tr>
<td>End Shock</td>
<td>0.64±.06</td>
<td>2.39±.14</td>
<td>1.65±.27</td>
<td>0.54±.07</td>
<td>-10.12±.23</td>
</tr>
<tr>
<td></td>
<td>0.47±.07</td>
<td>0.62±.08</td>
<td>1.65±.27</td>
<td>0.54±.07</td>
<td>-10.12±.23</td>
</tr>
<tr>
<td></td>
<td>1.91±.27</td>
<td>1.65±.27</td>
<td>0.94±.19</td>
<td>0.54±.07</td>
<td>-10.12±.23</td>
</tr>
<tr>
<td>S + 30'</td>
<td>0.38±.05</td>
<td>2.40±.54</td>
<td>0.60±.10</td>
<td>0.38±.05</td>
<td>-10.12±.23</td>
</tr>
<tr>
<td>S + 240'</td>
<td>0.86±.28</td>
<td>2.40±.54</td>
<td>0.60±.10</td>
<td>0.38±.05</td>
<td>-10.12±.23</td>
</tr>
</tbody>
</table>
LEGEND - TABLE II

Concentrations of glucose, glucose-6-phosphate (G-6-P) and lactate. Means ± SEM. Significant differences compared with corresponding control group. C = controls (n=10); G = glucagon treated (n=11); (S + 30' = 30 minutes post-resuscitation; S + 240' = 240 minutes post-resuscitation. *p<.05
<table>
<thead>
<tr>
<th>GROUP</th>
<th>GLUCOSE (um/g)</th>
<th>G-6-P (um/g)</th>
<th>LACTATE (um/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>5.14 ± 0.66</td>
<td>0.10 ± 0.03</td>
<td>1.54 ± 0.36</td>
</tr>
<tr>
<td>G</td>
<td>5.23 ± 0.59</td>
<td>0.06 ± 0.02</td>
<td>2.75 ± 0.58</td>
</tr>
<tr>
<td><strong>End Shock</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>17.50 ± 4.54</td>
<td>0.16 ± 0.03</td>
<td>12.04 ± 1.43</td>
</tr>
<tr>
<td>G</td>
<td>18.13 ± 6.29</td>
<td>0.13 ± 0.05</td>
<td>13.78 ± 1.75</td>
</tr>
<tr>
<td><strong>S + 30'</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>9.20 ± 2.42*</td>
<td>0.11 ± 0.03</td>
<td>13.38 ± 1.94</td>
</tr>
<tr>
<td>G</td>
<td>45.41 ± 12.33</td>
<td>0.16 ± 0.03</td>
<td>18.72 ± 5.06</td>
</tr>
<tr>
<td><strong>S + 240'</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>3.53 ± 0.80</td>
<td>0.09 ± 0.03</td>
<td>6.41 ± 1.81</td>
</tr>
<tr>
<td>G</td>
<td>4.78 ± 2.02</td>
<td>0.07 ± 0.02</td>
<td>11.63 ± 2.30</td>
</tr>
</tbody>
</table>
Means \( \pm \) SEM for \( O_2 \) delivery (cc/min) to the dog liver as well as portal vein and hepatic artery \( O_2 \) content (cc \( O_2/100cc \) blood).
Significant differences compared with corresponding control groups.
C = controls (n=10); G = glucagon treated (n=11). (S + 30’ = 30 minutes post-resuscitation; S + 240’ = 240 minutes post-resuscitation.
*p<.05, ** p<.001
<table>
<thead>
<tr>
<th>GROUP</th>
<th>O₂ DELIVERY (cc/min)</th>
<th>O₂ CONTENT Portal Vein (ccO₂/100cc)</th>
<th>O₂ CONTENT Hepatic Artery (ccO₂/100cc)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>82.0±12.9</td>
<td>11.6±1.2</td>
<td>15.5±0.8</td>
</tr>
<tr>
<td>G</td>
<td>97.8±15.4</td>
<td>14.6±1.2</td>
<td>17.1±1.0</td>
</tr>
<tr>
<td>End Shock</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>12.5±1.9</td>
<td>10.5±1.4</td>
<td>11.3±2.6</td>
</tr>
<tr>
<td>G</td>
<td>27.4±9.8</td>
<td>9.6±1.4</td>
<td>9.3±3.4</td>
</tr>
<tr>
<td>S + 30'</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>77.6±8.5</td>
<td>14.5±0.7</td>
<td>15.6±0.8</td>
</tr>
<tr>
<td>G</td>
<td>202.4±44.7**</td>
<td>16.8±1.0*</td>
<td>17.3±1.1</td>
</tr>
<tr>
<td>S + 240'</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>53.3±11.4</td>
<td>12.6±1.1</td>
<td>11.9±2.3</td>
</tr>
<tr>
<td>G</td>
<td>61.4±12.3</td>
<td>14.6±0.8</td>
<td>15.2±2.3</td>
</tr>
</tbody>
</table>
LEGEND - FIGURE I

Depiction of the experimental model. Means ± SEM for the arterial pressures are shown.
EXPERIMENTAL MODEL

ARTERIAL PRESSURE (mmHg)

150
100
50
0

BASELINE

END SHOCK SAMPLE

S + 30 MINS. SAMPLE

S + 240 MINS. SAMPLE

15 MINS.

90 MINS.

30 MINS.

30 MINS.

210 MINS.

SAMPLE

SAMPLE

SAMPLE
LEGEND - FIGURE II

Total flow (hepatic artery + portal vein) of the seven animals experiencing an increase after glucagon contracted with all Group I animals. Mean ± SEM is depicted.
TOTAL FLOW

cc./min.

<table>
<thead>
<tr>
<th></th>
<th>WITHOUT GLUCAGON</th>
<th>WITH GLUCAGON</th>
</tr>
</thead>
<tbody>
<tr>
<td>BASELINE</td>
<td>800 ± 50</td>
<td>600 ± 40</td>
</tr>
<tr>
<td>END SHOCK</td>
<td>200 ± 15</td>
<td>100 ± 20</td>
</tr>
<tr>
<td>S + 30'</td>
<td>1200 ± 60</td>
<td>1400 ± 70</td>
</tr>
<tr>
<td>S + 240'</td>
<td>400 ± 20</td>
<td>200 ± 10</td>
</tr>
</tbody>
</table>

$p < 0.05$